A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin

NCT01143246 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

196

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatorenal Syndrome

Interventions

DRUG: Terlipressin
DRUG: Placebo

Sponsor

Mallinckrodt